Piramal Pharma Ltd (PPLPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543635 | NSE: PPLPHARMA | Pharmaceuticals & Drugs | Small Cap

Piramal Pharma Share Price

178.45 -2.10 -1.16%
as on 05-Dec'25 09:52

Piramal Pharma Ltd (PPLPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543635 | NSE: PPLPHARMA | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Piramal Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Piramal Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
34.02
Market Cap:
23,999.6 Cr.
52-wk low:
179.6
52-wk high:
279.2

Is Piramal Pharma Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Piramal Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 16.2%9.9%3.6%8.3%12.4%-
Value Creation
Index
0.4-0.1-0.7-0.40.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,9393,3403,4434,3905,2865,035
Sales YoY Gr.-13.7%3.1%27.5%20.4%-
Adj EPS 5.22.9-0.22.85.25.3
YoY Gr.--45.1%-106.6%NA88.1%-
BVPS (₹) 40.342.243.150.555.858.3
Adj Net
Profit
533349-23.7367693706
Cash Flow from Ops. 34.724971.5358549-
Debt/CF from Ops. 4.84.622.83.22.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA16.5%20.4%
Adj EPS NANA22.1%88.1%
BVPSNANA9.8%10.4%
Share Price - - 8.7% -34.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
137.6-0.56.19.89.3
Op. Profit
Mgn %
21.114.32.813.719.216
Net Profit
Mgn %
18.110.5-0.78.413.114
Debt to
Equity
00.20.30.20.20.1
Working Cap
Days
0287329327310122
Cash Conv.
Cycle
06784727546

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Piramal Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 5.3 -0.2
TTM Sales (₹ Cr.) 5,035 8,936
BVPS (₹.) 58.3 60.8
Reserves (₹ Cr.) 6,417 6,748
P/BV 3.10 2.97
PE 34.02 0.00
From the Market
52 Week Low / High (₹) 179.55 / 279.20
All Time Low / High (₹) 61.65 / 307.85
Market Cap (₹ Cr.) 24,000
Equity (₹ Cr.) 1,329.3
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Piramal Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Piramal Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Piramal Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales2,9393,3403,4434,3905,286
Operating Expenses 2,3202,8653,3463,7914,277
Manufacturing Costs315367426431489
Material Costs1,2281,5621,7682,1092,246
Employee Cost 395448549614736
Other Costs 382488602637806
Operating Profit 619475985991,009
Operating Profit Margin (%) 21.1%14.2%2.8%13.7%19.1%
Other Income 198225341221239
Interest 557116107115
Depreciation 144165192205222
Exceptional Items 18-15-700
Profit Before Tax 687462124508911
Tax 1159554116220
Profit After Tax 57236870391691
PAT Margin (%) 19.4%11.0%2.0%8.9%13.1%
Adjusted EPS (₹)5.63.00.63.05.2
Dividend Payout Ratio (%)0%0%0%4%3%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 4,1015,1235,2626,6857,389
Share Capital 9951,1861,1931,3231,324
Reserves 3,1063,9374,0685,3626,065
Minority Interest00000
Debt1658671,3138961,009
Long Term Debt0477592364357
Short Term Debt165390720532652
Trade Payables5846477621,1081,185
Others Liabilities 1,0029429601,1911,376
Total Liabilities 5,8527,5798,2969,87910,958

Fixed Assets

Gross Block2,2603,2253,5653,7674,258
Accumulated Depreciation6337869631,1551,364
Net Fixed Assets 1,6272,4392,6022,6122,894
CWIP 121405417533327
Investments 1,5921,6301,7471,7083,105
Inventories4215368191,1531,205
Trade Receivables8409899101,3311,667
Cash Equivalents 15213764242178
Others Assets 1,1001,4441,7382,3001,582
Total Assets 5,8527,5798,2969,87910,958

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 3524972358549
PBT 669477124508911
Adjustment -3104351221265
Changes in Working Capital -228-168-43-293-393
Tax Paid -95-103-60-78-234
Cash Flow From Investing Activity -4,383-1,246-435-636-550
Capex -55-231-243-325-282
Net Investments -3,710-137-824061
Others -618-877-110-350-329
Cash Flow From Financing Activity 4,494896290451-62
Net Proceeds from Shares 3,448001,0503
Net Proceeds from Borrowing 0697134-287-33
Interest Paid -4-45-101-101-127
Dividend Paid 0-50-670-14
Others 1,050294324-211110
Net Cash Flow 146-100-73174-63

Finance Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)13.947.971.346.559.83
ROCE (%)16.219.863.648.3312.4
Asset Turnover Ratio0.520.510.450.510.52
PAT to CFO Conversion(x)0.060.681.030.920.79
Working Capital Days
Receivable Days100989789100
Inventory Days5051697879
Payable Days174144145162186

Piramal Pharma Ltd Stock News

Piramal Pharma Ltd FAQs

The current trading price of Piramal Pharma on 05-Dec-2025 09:52 is ₹178.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Piramal Pharma stood at ₹23,999.6.
The latest P/E ratio of Piramal Pharma as of 04-Dec-2025 is 34.02.
The latest P/B ratio of Piramal Pharma as of 04-Dec-2025 is 3.10.
The 52-week high of Piramal Pharma is ₹279.2 and the 52-week low is ₹179.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Pharma is ₹5,035 ( Cr.) .

About Piramal Pharma Ltd

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.

Business area of the company

The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×